CLDX

NASDAQ · Biotechnology

Celldex Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$32.98

-0.43 (-1.29%)

CLDX News1 articles

Celldex Shares Pull Back After Barzolvolimab Enrollment Milestone

Celldex Therapeutics shares retreated about 4% in premarket trading Thursday, giving back some of the prior session's 24% surge. The biotech completed patient enrollment for two key Phase 3 studies of its mast cell inhibitor barzolvolimab six months early.